Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study

Abstract Background Radical cystectomy is the gold-standard management for muscle-invasive bladder cancer, and there is debate concerning the comparative effectiveness of robotic-assisted (RARC) versus open radical cystectomy (ORC). Objective To compare utilization, perioperative, cost, and survival...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2016-07, Vol.70 (1), p.195-202
Main Authors: Hu, Jim C, Chughtai, Bilal, O’Malley, Padraic, Halpern, Joshua A, Mao, Jialin, Scherr, Douglas S, Hershman, Dawn L, Wright, Jason D, Sedrakyan, Art
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Bladder cancer
Carcinoma, Transitional Cell - surgery
Costs and cost analysis
Cystectomy
Cystectomy - adverse effects
Cystectomy - economics
Cystectomy - methods
Female
Health Care Costs
Home Care Services - statistics & numerical data
Humans
Length of Stay
Lymph node excision
Lymph Node Excision - methods
Male
Perioperative Period
Postoperative Complications - etiology
Robotic surgical procedures
Robotic Surgical Procedures - adverse effects
Robotic Surgical Procedures - economics
Robotic Surgical Procedures - statistics & numerical data
SEER Program
Survival Rate
Time Factors
Treatment Outcome
Urinary Bladder Neoplasms - surgery
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Radical cystectomy is the gold-standard management for muscle-invasive bladder cancer, and there is debate concerning the comparative effectiveness of robotic-assisted (RARC) versus open radical cystectomy (ORC). Objective To compare utilization, perioperative, cost, and survival outcomes of RARC versus ORC. Design, setting, and participants We identified bladder urothelial carcinoma treated with RARC ( n = 439) or ORC ( n = 7308) during 2002–2012 using the Surveillance, Epidemiology, and End Results Program-Medicare linked data. Intervention Comparison of RARC versus ORC. Outcome measurements and statistical analysis We used propensity score matching to compare perioperative and survival outcomes, including lymph node yield, perioperative complications, and healthcare costs. Results and limitations Utilization of RARC increased from 0.7% of radical cystectomies in 2002 to 18.5% in 2012 ( p < 0.001). Women comprised 13.9% versus 18.1% ( p = 0.007) of RARC versus ORC, respectively. RARC was associated with greater lymph node yield with 41.5% versus 34.9% having ≥10 lymph nodes removed (relative risk 1.1, 95% confidence interval [CI] 1.01–1.22, p = 0.03) and shorter mean length of hospitalization at 10.1 (± standard deviation 7.1) d versus 11.2 (± 8.6) d ( p = 0.004). While inpatient costs were similar, RARC was associated with increased home healthcare utilization (relative risk 1.14, 95% CI 1.04–1.26, p = 0.009) and higher 30-d ( p < 0.01) and 90-d ( p < 0.01) costs. With a median follow-up of 44 mo (interquartile range 16–78), overall survival (hazard ratio 0.88, 95% CI 0.74–1.05) and cancer-specific survival (hazard ratio 0.91, 95% CI 0.66–1.26) were similar. Conclusions RARC provides equivalent perioperative and intermediate term outcomes to ORC. Additional long-term and randomized studies are needed for continued comparative effectiveness assessment of RARC versus ORC. Patient summary Our population-based US study demonstrates that robotic-assisted radical cystectomy has similar perioperative and survival outcomes albeit at higher costs.
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2016.03.028